Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-204 in Lewy Body Dementia Psychosis
NCT07095465Phase 3Recruiting
- Sponsor
- Acadia Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of remlifanserin in Lewy body dementia (LBD), sponsored by Acadia Pharmaceuticals. Started Nov 2025; status: recruiting.
02
Drugs
remlifanserin
03
Conditions
Lewy body dementia (LBD)
Beyond the preview
Go deeper on NCT07095465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095465.